Thiogenesis Therapeutics Balance Sheet Health
Financial Health criteria checks 5/6
Thiogenesis Therapeutics has a total shareholder equity of CA$4.8M and total debt of CA$0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are CA$5.1M and CA$308.5K respectively.
Key information
0%
Debt to equity ratio
CA$0
Debt
| Interest coverage ratio | n/a |
| Cash | CA$4.97m |
| Equity | CA$4.76m |
| Total liabilities | CA$308.45k |
| Total assets | CA$5.06m |
Recent financial health updates
We're Keeping An Eye On Thiogenesis Therapeutics' (CVE:TTI) Cash Burn Rate
Nov 20
We Think Thiogenesis Therapeutics (CVE:TTI) Needs To Drive Business Growth Carefully
Jul 17Here's Why We're Not Too Worried About Thiogenesis Therapeutics' (CVE:TTI) Cash Burn Situation
Aug 25We're Not Very Worried About Thiogenesis Therapeutics' (CVE:TTI) Cash Burn Rate
May 01Recent updates
We're Keeping An Eye On Thiogenesis Therapeutics' (CVE:TTI) Cash Burn Rate
Nov 20We Think Thiogenesis Therapeutics (CVE:TTI) Needs To Drive Business Growth Carefully
Jul 17Here's Why We're Not Too Worried About Thiogenesis Therapeutics' (CVE:TTI) Cash Burn Situation
Aug 25We're Not Very Worried About Thiogenesis Therapeutics' (CVE:TTI) Cash Burn Rate
May 01Financial Position Analysis
Short Term Liabilities: TTI's short term assets (CA$5.1M) exceed its short term liabilities (CA$308.5K).
Long Term Liabilities: TTI has no long term liabilities.
Debt to Equity History and Analysis
Debt Level: TTI is debt free.
Reducing Debt: TTI had no debt 5 years ago.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: TTI has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: TTI has less than a year of cash runway if free cash flow continues to reduce at historical rates of 53.1% each year